top of page
Henry Shin, Ph.D.
Co-founder & Chief Executive Office
Dr. Shin received his Ph.D. in Physiology from the University of Oklahoma Health Sciences Center under Dr. Jian-Xing Ma, a renowned researcher in visual science and diabetic retinopathy. Dr. Shin has been deeply involved in ophthalmic research throughout his career, with a special interest in molecular mechanism of retinal degeneration and human blindness. Dr. Shin has extensive experience with development, application and optimization of molecular tools and animal models for investigating ocular diseases.
Adam Duerfeldt, Ph.D.
Co-founder & Faculty Collaborator
Associate professor, Dept. of Medicinal Chemistry, University of Minnesota
Dr. Duerfeldt obtained his Ph.D. in Medicinal Chemistry from the University of Kansas. After completing an American Cancer Society Postdoctoral Fellowship at The Scripps Research Institute, he began his independent research career at the University of Oklahoma. Dr. Duerfeldt’s expertise lies in structure-guided lead optimization and his research interests include 1) the development of chemical tools that can be utilized to enhance our understanding of disease mechanisms and 2) the development of new therapeutic leads for the treatment of cancers, bacterial infections, and ocular diseases.
Jian-Xing Ma, M.D./Ph.D.
Co-founder & Scientific Consultant
Chair, Dept. of Biochemistry, Wake Forest University
Dr. Ma is a leading expert in the field of Diabetic Retinopathy (DR) research who has identified and investigated various pathogenic mechanisms underlying diabetes complications. Dr. Ma has established many diabetic animal models, transgenic and knock-out mice as well as the assays and techniques for DR studies in his laboratory. He has been continously funded through NIH since 1998, and has published more than 200 peer-reviewed papers.
bottom of page